New Drugs Approvals Bring No Relief For Ailing Innovent Bio
seekingalpha.com
news
2022-10-18 17:47:00

wacomka The Hong Kong stock market's latest freefall hasn't spared anyone, including once highly sought medical stocks that tempted investors with the huge potential of China's fast-growing drug market. Even upbeat news on the commercialization of a promising new drug fails to excite these days, as former highflyer Innovent Biologics Inc. (1801.HK)(OTCPK:IVBIY)(OTCPK:IVBXF) has discovered lately. Last week the company made two announcements that would have been welcome in any other time. It began the week by saying the Chinese regulator had approved its rearranged during transfection (RET) kinase inhibitor Selpercatinib, which is the first of its category in the world to treat diseases including non-small cell lung cancer, medullary thyroid cancer and thyroid cancer.
